Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 10

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
 the calculation of diluted loss per common share as their effect would have been anti-dilutive. The Company did not pay
any dividends during the first three months of 2025 or 2024.

    9

Note 5. Segment Performance Measures
and Expenses

The Company operates in one segment for the research
and development of our product candidates. The Company’s chief operating decision maker (“CODM”) has been identified
as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing
performance for the entire Company based on consolidated financial information. Consequently, we view the entire organization as one reportable
segment and the strategic purpose of all operating activities (including general & administrative expenses) is to support that one
segment. As a pre-revenue research and development company, the CODM evaluates company-wide performance and allocates resources based
on non-financial research and development milestones achieved, and to a lesser extent, financial measures of performance such as clinical
development (research and development expenses) and general and administrative expenses incurred. Our CODM does not generally evaluate
our performance using asset or historical cash flow information.

The table below provides a summary of the significant
expense categories and consolidated net loss details provided to the CODM (in thousands):

 Schedule
of Significant Expense Categories and Consolidated Net Loss

    For the three months ended March 31, 

    (In thousands)  
    Change Increase (Decrease) 

    2025  
    2024  

    Operating Expenses: 

    Clinical Research 

    OVATION 
    $214  
    $287  
    $(73) 
     (25.4)%
  
    Vaccine 
     58  
     571  
     (513) 
     (89.8)%
  
    Other Clinical and regulatory 
     574  
     477  
     97  
     20.3%
  
    Subtotal 
     846  
     1,335  
     (489) 
     (36.6)%
  
    Non-Clinical R&D and CMC 

    OVATION 
     913  
     405  
     508  
     125.4%
  
    PlaCCine Vaccine 
     -  
     1,215  
     (1,215) 
     -%
  
    Manufacturing